Response rate with cetuximab used less than 3 months after immunotherapy (IO) for recurrent/metastatic head and neck squamous cell carcinomas (R/M HNSCC) compared to larger delay.

被引：0
|
作者：
Carulla, Yannick
Neidhardt, Eve-Marie
Karabajakian, Andy
Gauduchon, Thibault
Guevara, Hemerson
Roux, Pierre Eric
Zrounba, Philippe
Podeur, Fabien
Poupart, Marc
Excoffier, Aude
Fayette, Jerome
机构：
[1] Ctr Leon Berard, Lyon, France
[2] 28 Promenade Lea & Napoleon Bullukian, Lyon, France
[3] Owkin France, Paris, France
[4] Ctr Leon Berad, Lyon, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e18027
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Clinical trials outcomes of combined BKM120 and cetuximab compared to BKM120 in recurrent and/or metastatic squamous cell carcinoma of head and neck (R/M-SCCHN)
    Kim, Hye Ryun
    Kang, Han Na
    Yun, Mi Ran
    Lim, Sun Min
    Kim, Chang Gon
    Ahn, Myung-Ju
    Sun, Jong-Mu
    Kim, Joo-Hang
    Paik, Soonmyung
    Cho, Byoung Chul
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [32] Pembrolizumab (pembro) vs standard of care (SOC) for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): Phase 3 KEYNOTE-040 trial
    Cohen, E. E.
    Harrington, K. J.
    Le Tourneau, C.
    Dinis, J.
    Licitra, L.
    Ahn, M-J.
    Soria, A.
    Machiels, J-P.
    Mach, N.
    Mehra, R.
    Burtness, B.
    Wang, Y.
    Tuozzo, A. J.
    Swaby, R.
    Soulieres, D.
    ANNALS OF ONCOLOGY, 2017, 28
  • [33] First-Line Pembrolizumab With or Without Lenvatinib in Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC): Phase 3 LEAP-010 Study
    Harrington, Kevin
    Siu, Lillian L.
    Burtness, Barbara
    Cohen, Ezra
    Licitra, Lisa
    Rischin, Danny
    Zhu, Ying
    Okpara, Chinyere E.
    Pinheiro, Cecilia
    Swaby, Ramona F.
    Machiels, Jean-Pascal
    Tahara, Makoto
    ORAL ONCOLOGY, 2021, 118
  • [34] Preliminary safety and efficacy of toripalimab combined with cetuximab in platinum-refractory recurrent or metastatic head and neck squamous cell carcinoma (R/M-HNSCC): A phase Ib/II clinical trial.
    Guo, Ye
    Li, Zhendong
    Chen, Wantao
    Fang, Meiyu
    Liu, Zhigang
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [35] A randomized phase II study of cetuximab (C) every 2 weeks at either 500 or 750 mg/m2 for patients (Pts) with recurrent or metastatic (R/M) head and neck squamous cell cancer (HNSCC).
    Fury, M. G.
    Sherman, E. J.
    Lisa, D. M.
    Agarwal, N.
    Algazy, K. M.
    Brockstein, B.
    Langer, C. J.
    Lim, D.
    Mehra, R.
    Rajan, S. K.
    Jafri, N.
    Korte, S.
    Lipson, B.
    Yunus, F.
    Tanvetyanon, T.
    Smith-Marrone, S.
    Ng, K. K.
    Xiao, H.
    Haque, S.
    Pfister, D. G.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [36] Pembrolizumab with or Without Lenvatinib As First-line Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC): Phase 3 LEAP-010 Study
    Licitra, L.
    Tahara, M.
    Harrington, K.
    Hurtado de Mendoza, M. Olivera
    Guo, Y.
    Aksoy, S.
    Fang, M.
    Zurawski, B.
    Csoszi, T.
    Klochikhin, M.
    de Oliveira, T. B.
    Takahashi, S.
    Yang, M. H.
    Swiecicki, P. L.
    O'Hara, K.
    Shen, J.
    Wang, A.
    Gumuscu, B.
    Benjamin, K.
    Haddad, R. I.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 118 (05): : E2 - E3
  • [37] FIERCE-HN: A Multicenter, Randomized, Placebo-Controlled, Phase 3 Study of Ficlatuzumab plus Cetuximab in Pts W/ Recurrent or Metastatic (R/M) HPV-Negative Head and Neck Squamous Cell Carcinoma (HNSCC)
    Bauman, J.
    Allman, K.
    Haddad, R. I.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 120 (02): : E734 - E734
  • [38] FIERCE-HN: A Multicenter, Randomized, Placebo-controlled, Phase 3 Study of ficlatuzumab plus cetuximab in pts w/recurrent or Metastatic (R/M) HPV-negative Head and Neck Squamous Cell Carcinoma (HNSCC)
    Bauman, J.
    Allman, K.
    Haddad, R. I.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 118 (05): : E36 - E36
  • [39] Association of neutrophil-lymphocyte ratio (NLR) with clinical outcomes in patients (pts) with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) treated with combination of cetuximab and nivolumab (C plus N).
    Park, Robin
    Rind, Fahad
    Kristoff, Tyler
    Li, Jiannong
    Slebos, Robbert
    Thatikonda, Sowjanya
    Chaudhary, Ritu
    Poole, Maria
    Kaldas, David
    Farinhas, Joaquim
    Hernandez-Prera, Juan C.
    Kirtane, Kedar
    Rocco, James William
    Bhateja, Priyanka
    Steuer, Conor Ernst
    Saba, Nabil F.
    Bonomi, Marcelo Raul
    Chung, ChristineH.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [40] Long-term response to second-line afatinib in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): Analysis of the LUX-Head & Neck 1 (LHN1) trial
    Machiels, J-P.
    de Castro, G., Jr.
    de Souza Viana, L.
    Galiulin, R.
    Tahara, M.
    Nicolau, U. R.
    Le Tourneau, C.
    Okami, K.
    Vladimirov, V.
    Izmailov, A.
    Hoermann, K.
    Licitra, L.
    Haddad, R.
    Cohen, E.
    Dupuis, N.
    Love, J.
    Zografos, E.
    Ehrnrooth, E.
    Fayette, J.
    ANNALS OF ONCOLOGY, 2017, 28
12345